Shanghai Pharmaceuticals Holding バランスシートの健全性
財務の健全性 基準チェック /56
Shanghai Pharmaceuticals Holding has a total shareholder equity of CN¥83.2B and total debt of CN¥48.4B, which brings its debt-to-equity ratio to 58.2%. Its total assets and total liabilities are CN¥223.7B and CN¥140.6B respectively. Shanghai Pharmaceuticals Holding's EBIT is CN¥8.6B making its interest coverage ratio -346. It has cash and short-term investments of CN¥42.4B.
主要情報
58.2%
負債資本比率
CN¥48.42b
負債
| インタレスト・カバレッジ・レシオ | -346x |
| 現金 | CN¥42.39b |
| エクイティ | CN¥83.16b |
| 負債合計 | CN¥140.58b |
| 総資産 | CN¥223.74b |
財務の健全性に関する最新情報
更新なし
Recent updates
財務状況分析
短期負債: S1R's short term assets (CN¥173.8B) exceed its short term liabilities (CN¥129.5B).
長期負債: S1R's short term assets (CN¥173.8B) exceed its long term liabilities (CN¥11.1B).
デット・ツー・エクイティの歴史と分析
負債レベル: S1R's net debt to equity ratio (7.3%) is considered satisfactory.
負債の削減: S1R's debt to equity ratio has reduced from 64.8% to 58.2% over the past 5 years.
債務返済能力: S1R's debt is not well covered by operating cash flow (11.8%).
インタレストカバレッジ: S1R earns more interest than it pays, so coverage of interest payments is not a concern.